Radiopharmaceutical approval timeline

Regulatory approvals of therapeutic and diagnostic radiopharmaceuticals, newest first; every row links to its source.

United States (FDA)

  1. 31 July 2026

    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Therapy

    Indication expansion: with ARPI therapy, PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S; formerly hormone-sensitive) prostate cancer (PSMAddition); patients selected with Locametz or another approved PSMA PET agent

    FDA · primary source ↗

  2. 28 March 2025

    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Therapy

    Indication expansion: PSMA-positive mCRPC after ARPI in patients appropriate to delay taxane chemotherapy (PSMAfore)

    FDA · primary source ↗

  3. 20 March 2025

    Gozellix (kit for Ga 68 gozetotide) Diagnostic

    PSMA PET in prostate cancer (kit with a longer shelf life)

    FDA · primary source ↗

  4. 27 September 2024

    Flyrcado (flurpiridaz F 18) Diagnostic

    PET myocardial perfusion imaging in known or suspected coronary artery disease

    FDA · primary source ↗

  5. 23 April 2024

    Lutathera (lutetium Lu 177 dotatate) Therapy

    SSTR-positive GEP-NETs in children aged 12 and older (first paediatric radiopharmaceutical therapy approval)

    FDA · primary source ↗

  6. 25 May 2023

    Posluma (flotufolastat F 18) Diagnostic

    PSMA PET in prostate cancer

    FDA · primary source ↗

  7. 23 March 2022

    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Therapy

    PSMA-positive mCRPC after androgen receptor pathway inhibition and taxane chemotherapy

    FDA · primary source ↗

  8. 23 March 2022

    Locametz (kit for Ga 68 gozetotide) Diagnostic

    PSMA PET; the first diagnostic agent approved for selecting patients for Lu-177 PSMA therapy

    FDA · primary source ↗

  9. 17 December 2021

    Illuccix (kit for Ga 68 gozetotide) Diagnostic

    PSMA PET in prostate cancer

    FDA · primary source ↗

  10. 27 May 2021

    Pylarify (piflufolastat F 18) Diagnostic

    PSMA PET in prostate cancer (suspected metastasis or PSA-based suspected recurrence)

    FDA · primary source ↗

  11. 1 December 2020

    Ga 68 PSMA-11 (UCLA, UCSF) (gallium Ga 68 PSMA-11) Diagnostic

    PET of PSMA-positive lesions in prostate cancer (first PSMA PET approval)

    FDA · primary source ↗

  12. 3 September 2020

    Detectnet (copper Cu 64 dotatate) Diagnostic

    PET localisation of SSTR-positive neuroendocrine tumours

    FDA · primary source ↗

  13. 28 May 2020

    Tauvid (flortaucipir F 18) Diagnostic

    PET estimate of tau neurofibrillary tangles in adults with cognitive impairment evaluated for Alzheimer's disease

    FDA · primary source ↗

  14. 20 May 2020

    Cerianna (fluoroestradiol F 18) Diagnostic

    PET detection of oestrogen receptor-positive lesions in recurrent or metastatic breast cancer (adjunct to biopsy)

    FDA · primary source ↗

  15. 21 August 2019

    Ga 68 DOTATOC (gallium Ga 68 dotatoc) Diagnostic

    PET localisation of SSTR-positive neuroendocrine tumours

    FDA · primary source ↗

  16. 26 January 2018

    Lutathera (lutetium Lu 177 dotatate) Therapy

    SSTR-positive gastroenteropancreatic neuroendocrine tumours in adults

    FDA · primary source ↗

  17. 1 June 2016

    Netspot (kit for Ga 68 dotatate) Diagnostic

    PET localisation of SSTR-positive neuroendocrine tumours

    FDA · primary source ↗

  18. 27 May 2016

    Axumin (fluciclovine F 18) Diagnostic

    PET in men with suspected prostate cancer recurrence based on elevated PSA after prior treatment

    FDA · primary source ↗

  19. 15 May 2013

    Xofigo (radium Ra 223 dichloride) Therapy

    Castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases

    FDA · primary source ↗

European Union (EMA, first EU authorisation)

  1. 9 December 2022

    Pluvicto (lutetium (177Lu) vipivotide tetraxetan) Therapy

    Progressive PSMA-positive mCRPC after ARPI and taxane chemotherapy (first EU authorisation)

    EMA · primary source ↗

  2. 9 December 2022

    Locametz (gozetotide (kit for Ga 68)) Diagnostic

    PSMA PET in prostate cancer, including selection of patients for PSMA-targeted therapy

    EMA · primary source ↗

  3. 26 September 2017

    Lutathera (lutetium (177Lu) oxodotreotide) Therapy

    Unresectable or metastatic, progressive, well-differentiated SSTR-positive GEP-NETs in adults

    EMA · primary source ↗

  4. 22 May 2017

    Axumin (fluciclovine (18F)) Diagnostic

    PET in suspected prostate cancer recurrence after primary treatment

    EMA · primary source ↗

  5. 8 December 2016

    SomaKit TOC (edotreotide (kit for Ga 68)) Diagnostic

    PET localisation of well-differentiated gastroenteropancreatic neuroendocrine tumours

    EMA · primary source ↗

  6. 13 November 2013

    Xofigo (radium Ra 223 dichloride) Therapy

    Castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases (first EU authorisation)

    EMA · primary source ↗

Türkiye (TİTCK)

  1. 24 October 2025

    Tektrotyd (HYNIC-[D-Phe1,Tyr3]-oktreotid) Diagnostic

    Somatostatin analogue kit labelled with Tc-99m for SSTR scintigraphy (licence no 2025/473)

    TİTCK · primary source ↗

  2. 9 February 2023

    MON.FDOPA (18F) ([18F] florodopa) Diagnostic

    F-18 FDOPA PET agent (licence no 2023/28)

    TİTCK · primary source ↗

  3. 29 November 2022

    GalliaPharm (germanyum-68/galyum-68 jeneratörü) Diagnostic

    Ge-68/Ga-68 radionuclide generator for preparing Ga-68-labelled kits (licence no 2022/687)

    TİTCK · primary source ↗

  4. 14 October 2021

    Ankükolin (18F) ([18F] florokolin) Diagnostic

    F-18 fluorocholine PET agent (licence no 2021/378)

    TİTCK · primary source ↗

  5. 19 December 2019

    MON.LUTEC (lutesyum (177Lu) klorür) Therapy

    Lu-177 radiopharmaceutical precursor for radiolabelling, not for direct administration (licence no 2019/703)

    TİTCK · primary source ↗

  6. 10 October 2019

    Vizamyl ((18F) flutemetamol) Diagnostic

    Amyloid PET agent (licence no 2019/515)

    TİTCK · primary source ↗

  7. 6 June 2016

    Xofigo (radyum-223 diklorür) Therapy

    Ra-223 dichloride solution for injection (licence no 2016/473)

    TİTCK · primary source ↗

Sources: FDA approval letters and Drugs@FDA; for the EU, the European Commission Union Register decision granting the first authorisation; for Türkiye, the TİTCK list of licensed human medicinal products (13 November 2026). EU rows show the first authorisation only, not later indication extensions. Lutathera, Pluvicto and Locametz are not on the TİTCK list as of that date. Licensing differs by country; this list is not treatment advice.